Guardant Health(US:GH) Seeking Alpha·2026-01-13 03:15Core Insights - Guardant Health aims to provide individuals with more time free from disease, having pioneered the first liquid biopsy test for cancer therapy selection over 10 years ago [2] - The company has tested over 1 million patients and has received orders from over 12,000 oncologists and thousands of primary care physicians [2] - Guardant Health has invested approximately $2 billion in R&D to develop innovative products and establish itself as a leader in the liquid biopsy market [3] Company Overview - Guardant Health has expanded its offerings to include recurrence monitoring and cancer screening, demonstrating its commitment to helping more patients [2] - The company has built a world-class commercial organization, indicating strong operational capabilities and market presence [3] - Guardant Health believes it is still in the early stages of its growth and innovation journey [3]